Explicit
Shaping the Future of MS Treatment: The Role of Generics and Biosimilars with high cost drugs pharmacist Lucy Wessels
Apr 10, 2024 ·
34m 48s
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
In this episode we delve into the evolving landscape of multiple sclerosis treatment, focusing on generics and biosimilars. It features a conversation with pharmacist Lucy Wessels, highlighting the safety, effectiveness,...
show more
In this episode we delve into the evolving landscape of multiple sclerosis treatment, focusing on generics and biosimilars. It features a conversation with pharmacist Lucy Wessels, highlighting the safety, effectiveness, and cost benefits of generics and biosimilars in managing MS. The discussion emphasizes the importance of patient education, collaborative decision-making with healthcare providers, and dispelling misconceptions like the 'nocebo' effect around these treatment option.
00:00 Welcome and Introduction to the Episode
01:06 Understanding Generics and Biosimilars in MS Treatment
03:42 Diving Deeper: The Difference Between Generics and Biosimilars
11:58 Addressing Concerns: Side Effects and Tolerability
14:34 Enhancing Patient Understanding and Acceptance
20:22 The Nocebo Effect and Its Impact on Treatment Perception
24:34 Future of MS Treatment: Embracing Generics and Biosimilars
31:52 Concluding Thoughts and Key Takeaways
show less
00:00 Welcome and Introduction to the Episode
01:06 Understanding Generics and Biosimilars in MS Treatment
03:42 Diving Deeper: The Difference Between Generics and Biosimilars
11:58 Addressing Concerns: Side Effects and Tolerability
14:34 Enhancing Patient Understanding and Acceptance
20:22 The Nocebo Effect and Its Impact on Treatment Perception
24:34 Future of MS Treatment: Embracing Generics and Biosimilars
31:52 Concluding Thoughts and Key Takeaways
Information
| Author | Dr Agne Straukiene |
| Website | - |
| Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
